Important news
1. U.S. Secretary of Commerce Lutnick: Tariffs will take effect on August 1.
2. The Shanghai Stock Exchange held a symposium on equity investment institutions to implement the "1+6" policy of the Science and Technology Innovation Board.
3. The Civil Aviation Administration of China established a leading group for general aviation and low-altitude economy.
4. The Ministry of Finance: Take relevant measures on medical devices imported from the European Union in government procurement activities.
5. Renhuai, Guizhou Province, fully launched a special governance action for the liquor market, and the local sauce liquor industry issued a self-discipline proposal.
6. Nearly 60 A-share listed companies released their performance forecasts for the first half of 2025, and 13 of them had a year-on-year increase in net profit of more than 100%.
Individual stock news
1. China Shipbuilding: The absorption and merger of China Heavy Industry was approved by the Shanghai Stock Exchange.
2. Nanjing Business Travel: The controlling shareholder intends to reform and reorganize.
3. Xinpengwei: Net profit in the first half of the year is expected to increase by about 104% year-on-year.
4. Yuyin Shares: The actual controller plans to reduce its holdings of no more than 3% of the company's shares.
5. Shaoyang Hydraulics: Plans to purchase 100% of Xinchenghangrui's shares, and the stock will resume trading on July 7.
6. Guotou Zhonglu: Plans to purchase 100% of the shares of the Institute of Electronics, and the stock will resume trading on July 7.
7. Jinyi Culture: Plans to disclose the "2025 Semi-Annual Report" on August 30, 2025.
8. Tianmao Group: The company's stock has been issued a delisting risk warning, and the stock abbreviation has been changed to "*ST Tianmao".
9. Weiming Pharmaceutical: The stock has been issued other risk warnings since the opening of the market on July 8, and the abbreviation has been changed to "ST Weiming".
10. *ST Guangdao: The cumulative increase in stock price from June 25 to July 4 deviated from the Beijing Stock Exchange 50 Index by more than 119%, and the stock was suspended for inspection.
11. Guangshengtang: The innovative hepatitis B treatment drug GST-HG131 is planned to be included in the breakthrough treatment variety and is still in the public announcement period.
12. Celly Medical: There is still significant uncertainty as to whether the trial of its joint venture's therapeutic antihypertensive vaccine project will be successful.